Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for the intestinal barrier — teduglutide, larazotide acetate, BPC-157 and KPV — separating one Grade-A drug for a different condition from failed, abandoned or preclinical-only 'leaky gut' claims.
Immune, Gut & Longevity12 MIN READ
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for inflammatory bowel disease — BPC-157, KPV, thymosin alpha-1 and larazotide acetate — separating decades of rodent colitis data from the near-total absence of human IBD trials.
Immune, Gut & Longevity12 MIN READ
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for IBS — the FDA-approved GC-C agonists linaclotide and plecanatide, plus larazotide, BPC-157 and KPV — separating real human trials from preclinical promise and marketing hype.
Immune, Gut & Longevity12 MIN READ
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for autoimmune modulation — larazotide, thymosin alpha-1, ARA-290 and KPV — separating real human trials from preclinical promise, and flagging the bidirectional immune risk.
Immune, Gut & Longevity12 MIN READ
Peptide EncyclopediaA clinical monograph on larazotide acetate (AT-1001) — the gut tight-junction regulator developed for celiac disease. Real Phase 2 symptom data, a failed Phase 3, and an unapproved 2026 legal status.
Peptide Encyclopedia11 MIN READ